Publication:
Possible anti-inflammatory, antioxidant, and neuroprotective effects of apigenin in the setting of mild traumatic brain injury: an investigation*

Simple item page
dc.contributor.authorKOYUNCUOĞLU, TÜRKAN
dc.contributor.authorYÜKSEL, MERAL
dc.contributor.authorPEKER EYÜBOĞLU, İREM
dc.contributor.authorAKAKIN, DİLEK
dc.contributor.authorsKuru Bektasoglu P., Demir D., Koyuncuoglu T., YÜKSEL M., PEKER EYÜBOĞLU İ., Karagoz Koroglu A., AKAKIN D., Yildirim A., Celikoglu E., Gurer B.
dc.date.accessioned2022-10-26T07:39:49Z
dc.date.available2022-10-26T07:39:49Z
dc.date.issued2022-10-01
dc.description.abstractObjective Apigenin is a plant flavone proven with biological properties such as anti-inflammatory, antioxidant, and antimicrobial effects. This study, it was aimed to examine the possible anti-inflammatory, antioxidant, and neuroprotective effects of apigenin in the setting of the mild traumatic brain injury (TBI) model. Methods Wistar albino male rats were randomly assigned to groups: control (n = 9), TBI (n = 9), TBI + vehicle (n = 8), and TBI + apigenin (20 and 40 mg/kg, immediately after trauma; n = 6 and n = 7). TBI was performed by dropping a 300 g weight from a height of 1 m onto the skull under anesthesia. Neurological examination and tail suspension tests were applied before and 24 h after trauma, as well as Y-maze and object recognition tests, after that rats were decapitated. In brain tissue, luminol- and lucigenin-enhanced chemiluminescence levels and cytokine ELISA levels were measured. Histological damage was scored. Data were analyzed with one-way ANOVA. Results After TBI, luminol (p < .001) and lucigenin (p < .001) levels increased, and luminol and lucigenin levels decreased with apigenin treatments (p < .01-.001). The tail suspension test score increased with trauma (p < .01). According to the pre-traumatic values, the number of entrances to the arms (p < .01) in the Y-maze decreased after trauma (p < .01). In the object recognition test, discrimination (p < .05) and recognition indexes (p < .05) decreased with trauma. There was no significant difference among trauma apigenin groups in behavioral tests. Interleukin (IL)-10 levels, one of the anti-inflammatory cytokines, decreased with trauma (p < .05), and increased with 20 and 40 mg apigenin treatment (p < .001 and p < .01, respectively). The histological damage score in the cortex was decreased in the apigenin 20 mg treatment group significantly (p < .05), but the decrease observed in the apigenin 40 mg group was not significant. Conclusion The results of this study revealed that apigenin 20 and 40 mg treatment may have neuroprotective effects in mild TBI via decreasing the level of luminol and lucigenin and increasing the IL-10 levels. Additionally, apigenin 20 mg treatment ameliorated the trauma-induced cortical tissue damage.
dc.identifier.citationKuru Bektasoglu P., Demir D., Koyuncuoglu T., YÜKSEL M., PEKER EYÜBOĞLU İ., Karagoz Koroglu A., AKAKIN D., Yildirim A., Celikoglu E., Gurer B., "Possible anti-inflammatory, antioxidant, and neuroprotective effects of apigenin in the setting of mild traumatic brain injury: an investigation*", IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2022
dc.identifier.doi10.1080/08923973.2022.2130076
dc.identifier.issn0892-3973
dc.identifier.urihttps://hdl.handle.net/11424/282631
dc.language.isoeng
dc.relation.ispartofIMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTemel Eczacılık Bilimleri
dc.subjectEczacılık
dc.subjectMeslek Bilimleri
dc.subjectFarmasötik Toksikoloji
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectBasic Pharmaceutics Sciences
dc.subjectPharmacology and Therapeutics
dc.subjectProfessional Sciences
dc.subjectPharmaceutical Toxicology
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectNatural Sciences
dc.subjectİmmünoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectTOKSİKOLOJİ
dc.subjectIMMUNOLOGY
dc.subjectLife Sciences (LIFE)
dc.subjectPHARMACOLOGY & PHARMACY
dc.subjectPHARMACOLOGY & TOXICOLOGY
dc.subjectTOXICOLOGY
dc.subjectToksikoloji
dc.subjectFarmakoloji
dc.subjectFarmakoloji, Toksikoloji ve Eczacılık (çeşitli)
dc.subjectGenel Farmakoloji, Toksikoloji ve Eczacılık
dc.subjectFarmakoloji (tıbbi)
dc.subjectİlaç Rehberleri
dc.subjectGenel İmmünoloji ve Mikrobiyoloji
dc.subjectSağlık, Toksikoloji ve Mutajenez
dc.subjectFizik Bilimleri
dc.subjectPharmacy
dc.subjectToxicology
dc.subjectPharmacology
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectPharmacology (medical)
dc.subjectDrug Guides
dc.subjectImmunology
dc.subjectGeneral Immunology and Microbiology
dc.subjectHealth, Toxicology and Mutagenesis
dc.subjectPhysical Sciences
dc.subjectApigenin
dc.subjectinflammation
dc.subjectoxidative stress
dc.subjecttraumatic brain injury
dc.subjectneuroprotection
dc.subjectCEREBRAL ISCHEMIC-INJURY
dc.subjectNECROSIS-FACTOR-ALPHA
dc.subjectRAT-BRAIN
dc.subjectTNF-ALPHA
dc.subjectYGY-E
dc.subjectEXPRESSION
dc.subjectBARRIER
dc.subjectMODEL
dc.subjectINTERLEUKIN-1
dc.subjectIL-6
dc.titlePossible anti-inflammatory, antioxidant, and neuroprotective effects of apigenin in the setting of mild traumatic brain injury: an investigation*
dc.typearticle
dspace.entity.typePublication
local.avesis.id61e33339-7d54-4e7d-80e4-747c793d1681
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublicatione146f762-5a31-46c5-a898-7594b85c6da6
relation.isAuthorOfPublication8b13d479-2f3b-4180-bc71-7ad5a5625f1b
relation.isAuthorOfPublication1f54690f-f9ee-455c-96a9-fe3655fc2d23
relation.isAuthorOfPublicationc97c0ebf-ffce-4b27-a933-941a53767b0d
relation.isAuthorOfPublication.latestForDiscoverye146f762-5a31-46c5-a898-7594b85c6da6

Files

Collections

Research Outputs